NCT02272595|Completed
Rational Therapeutics Based on Matched Tumor and Normal Tissue
A Study to Select Rational Therapeutics Based on the Analysis of Matched Tumor and Normal Biopsies in Subjects With Advanced Malignancies
Loading search results
A Study to Select Rational Therapeutics Based on the Analysis of Matched Tumor and Normal Biopsies in Subjects With Advanced Malignancies
Sponsor study identifier
observational
3
4 countries
4
Study Start
November 4, 2014
Actual (reported)Primary Completion
January 11, 2022
Actual (reported)Study Completion
January 11, 2022
Actual (reported)The goal of this laboratory research study is to learn if using molecular information (matched therapy) or not using molecular information and having the study doctor choose the therapy based on your past experience are more effective ways to choose the best cancer treatment for you. This is an investigational study. Up to 200 participants will take part in this study. Up to 50 will be enrolled at MD Anderson.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 11, 2022
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 20, 2014
Actual (reported)October 23, 2014
Actual (reported)November 4, 2014
Actual (reported)January 11, 2022
Actual (reported)January 11, 2022
Actual (reported)Progression-Free Survival (PFS)
Progression-free survival (PFS) of the last therapeutic line (PFS1) before entering into study, with the PFS2 under study treatment. A clinical meaningful improvement is defined as demonstrating a PFS ratio (PFS2/PFS1) of being 1.5 or better.
2 - 3 weeks after treatment begins
Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
Cancer patients from University of Texas MD Anderson Cancer Center in Houston, Texas, Cancer Institute Gustave Roussy in Villejuif, France, Vall D'Hebron University Hospital in Barcelona, Spain, and Chaim Sheba Medical Center at Tel Hasomer in Ramat Gan, Israel
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Cancer Institute Gustave Roussy
Villejuif, 94805, France
Chaim Sheba Medical Center at Tel Hasomer
Ramat Gan, Israel
Vall D'Hebron University Hospital
Barcelona, 08035, Spain
Blood (about 2 teaspoons) drawn initially and again about 2-3 weeks after chosen treatment begins.
Apostolia M. Tsimberidou, MD, PHD
M.D. Anderson Cancer Center
3 participants (actual enrollment reported by the registry).
First Submitted
October 20, 2014
First Posted
October 23, 2014
Study Start
November 4, 2014
Actual (reported)Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
January 11, 2022
Actual (reported)Study Completion
January 11, 2022
Actual (reported)Last Updated
February 15, 2022
Record last verified: 2022-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: